Murilo Freitas – Page 24

FDA Roundup: March 22, 2024

Murilo Freitas - 20:45, 21 de March de 2024227

FDA Roundup: March 22, 2024
http://www.fda.gov/news-events/press-announcements/fda-roundup-march-22-2024

FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy

Murilo Freitas - 22:29, 20 de March de 2024275

FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy
http://www.fda.gov/news-events/press-announcements/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy

rss

Vyaire Medical, Inc. Recalls AirLife Manual Resuscitators Due to Manufacturing Defect That Can Lead to Injury or Death

Murilo Freitas - 04:00, 20 de March de 2024207

Vyaire recalls AirLife manual resuscitators because a manufacturing defect could result in patients not receiving enough ventilation, leading to injury or death.

http://www.fda.gov/medical-devices/medical-device-recalls/vyaire-medical-inc-recalls-airlife-manual-resuscitators-due-manufacturing-defect-can-lead-injury-or

rss

Abiomed Recalls the Instructions for Use for Impella Left Sided Blood Pumps due to Perforation Risks

Murilo Freitas - 04:00, 20 de March de 2024144

The Impella device’s catheter could cut through the wall of the left ventricle.

http://www.fda.gov/medical-devices/medical-device-recalls/abiomed-recalls-instructions-use-impella-left-sided-blood-pumps-due-perforation-risks

rss

Pyramid Wholesale Issues Recall of Various Brands of Products Sold as Dietary Supplements for Sexual Enhancement Because They Contain Undeclared Prescription Drugs Including Sildenafil (Viagra) and/or Tadalafil (Cialis)

Murilo Freitas - 04:00, 19 de March de 2024295

Pyramid Wholesale is issuing a recall of various brands of products sold as dietary supplements for sexual enhancement because they contain undeclared prescription drugs including Sildenafil (Viagra) and/or Tadalafil (Cialis).

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/pyramid-wholesale-issues-recall-various-brands-products-sold-dietary-supplements-sexual-enhancement

rss

Voluntary Removal Announcement for the InfuTronix Nimbus Ambulatory Infusion Pump System

Murilo Freitas - 04:00, 19 de March de 2024186

InfuTronix, LLC has announced a voluntary recall of the Nimbus Ambulatory Infusion Pump System, including Nimbus II PainPro, Nimbus II Flex, Nimbus II Plus, Nimbus II EpiD and Nimbus II EMS from the US Market due to a high number (3698) of customer complaints related to the Nimbus Infusion Pump sys

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/voluntary-removal-announcement-infutronix-nimbus-ambulatory-infusion-pump-system

rss

FDA Roundup: March 19, 2024

Murilo Freitas - 20:08, 18 de March de 2024228

FDA Roundup: March 19, 2024
http://www.fda.gov/news-events/press-announcements/fda-roundup-march-19-2024

rss

FDA Approves First Gene Therapy for Children with Metachromatic Leukodystrophy

Murilo Freitas - 17:52, 17 de March de 2024215

FDA Approves First Gene Therapy for Children with Metachromatic Leukodystrophy
http://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-children-metachromatic-leukodystrophy

rss

Sleepnet Corporation Issues Worldwide Recall of CPAP and BIPAP Masks with Magnets Due to Potential Interference with Certain Medical Implants

Murilo Freitas - 04:00, 17 de March de 2024285

Hampton, NH – On March 1, 2024, Sleepnet Corporation initiated a worldwide recall for all CPAP and BIPAP masks with magnets due to potential interference with certain medical devices. When a magnet comes into close proximity to certain medical implants or metallic implants, it could interfere with t

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sleepnet-corporation-issues-worldwide-recall-cpap-and-bipap-masks-magnets-due-potential-interference

Home Posts Movies

Meet Judit Rius Sanjuan, the new director of IMT

Murilo Freitas - 11:57, 18 de January de 20242,398

The new director of the Department of Innovation, Access to Medicines and Health Technologies (IMT), Judit Rius Sanjuan, tells us about the challenges and opportunities they are working on to reduce gaps and inequities in access to medicines and essential technologies, as well as to increase innovation.